Physician profile
Julia Schrogin
NPI 1245930676
$1,305.81
in general payments reported to CMS, 2019-2025
17 companies · $695 in 2025
The $695 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $263 · 2024: $348 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.91 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $196.42 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $163.01 | 2025 | Korlym |
| Averitas Pharma INC. | $130.00 | 2023 | Qutenza |
| Argenx US, INC. | $125.00 | 2025 | Vyvgart |
| Mayne Pharma Commercial LLC | $125.00 | 2025 | |
| Shield Therapeutics INC | $123.74 | 2024 | |
| Neurocrine Biosciences, INC. | $108.64 | 2024 | Ingrezza |
| Astellas Pharma US INC | $97.54 | 2023 | Veozah |
| Exact Sciences Corporation | $41.63 | 2023-2025 | Cologuard Collection Kit |
| Phadia US INC. | $40.16 | 2024-2025 | Immunocap |
| Hologic Sales and Service, LLC | $27.79 | 2024 | Aptima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.89 | 2025 | Xifaxan |
| Lilly USA, LLC | $23.64 | 2024 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $23.47 | 2025 | Rexulti |
| Dexcom, INC. | $23.30 | 2024 | Dexcom G6 Transmitter |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.95 | 2023 | |
| Abbvie INC. | $15.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Schrogin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.